5 Key Takeaways

• 1

  The Bausch + Lomb TENEO Excimer Laser Platform is the first FDA-approved excimer laser in 17 years for treating myopia and myopic astigmatism.

• 2

  TENEO features a compact design with the smallest footprint of any laser in the U.S., enhancing efficiency and ease of use for surgeons.

• 3

  The platform's internal nomogram streamlines the LASIK process, reducing errors and improving treatment speed based on manifest refraction.

• 4

  With a high-speed laser pulse rate of 500 Hz, TENEO achieves precise treatments in approximately 1.2 seconds per diopter.

• 5

  Clinical trials demonstrated that TENEO provides superior visual outcomes compared to glasses or contacts, enhancing patient satisfaction.